It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.
COVID-19 pandemic is a global health risk, but our understanding on the induced durable immunity remains scarce. Here the authors assess antibody responses in 869 convalescent COVID-19 patients to find that specific antibody titers reduce with time, and the RBD-IgG positive rate exceed 70% at 12 month post diagnosis, with male and older patients showing stronger responses.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China
2 Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China; Beijing Tiantan Biological Products Co., Ltd, Beijing, China
3 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China; Beijing Tiantan Biological Products Co., Ltd, Beijing, China
4 Beijing Tiantan Biological Products Co., Ltd, Beijing, China
5 Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China
6 Wuhan Institute of Biological Products Co. Ltd, Wuhan, China (GRID:grid.433798.2) (ISNI:0000 0004 0619 8601)
7 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China (GRID:grid.433798.2)
8 Beijing Tiantan Biological Products Co., Ltd, Beijing, China (GRID:grid.433798.2)
9 China National Biotec Group Company Limited, Beijing, China (GRID:grid.433798.2)
10 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China (GRID:grid.433798.2); Beijing Tiantan Biological Products Co., Ltd, Beijing, China (GRID:grid.433798.2)
11 Shanghai Jiao Tong University of Medicine, Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, National Research Center for Translational Medicine, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
12 China National Biotec Group Company Limited, Beijing, China (GRID:grid.16821.3c)